AllSci News
QurCan lands Lilly deal to advance CNS and PNS nucleic acid therapies
Toronto-based QurCan Therapeutics has entered an exclusive research and collaboration agreement with Eli Lilly and Company (NYSE: LLY) to develop nucleic...
Second negative CHMP trend vote clouds MaaT Pharma's European path for MaaT013
France-based MaaT Pharma (Euronext: MAAT) received a second negative trend vote from the European Medicines Agency's (EMA) Committee for Medicinal Products...
FDA approves Curium’s Bexlutry, challenging Novartis’ Lutathera monopoly in GEP-NETs
The US FDA has approved Bexlutry (lutetium Lu 177 dotatate), a radioligand therapy from Boston-based Curium, for the treatment of adults with somatostatin...
FDA opens expedited IND pathway with rolling pre-IND review
The agency announced today the final design of its Expedited Investigational New Drug (IND) Pilot and opened applications for participation, with a deadline...
Cellectis exits CAR-T development to focus on in vivo gene editing for metabolic diseases
Cellectis (Euronext Growth: ALCLS / Nasdaq: CLLS), the Paris-based gene editing company, is ending internal development of its allogeneic CAR-T programs and...
QL Bio completes RMB 30m Series C+ financing to advance metabolic disease pipeline
Beijing QL Biopharmaceutical Co., Ltd. has raised nearly RMB 300 million (USD 44.7 million) in a Series C+ financing round led by Cathay Capital, with...
Definium’s LSD therapy posts second positive Phase III GAD result
New York-based Definium Therapeutics (Nasdaq: DFTX) has completed its pivotal Phase III GAD efficacy readouts with a second consecutive positive result,...
PDS Biotech secures USD 11.3m initial PIPE to fund PDS0301 Phase III protocol submission
Princeton, New Jersey-based PDS Biotechnology Corporation (Nasdaq: PDSB) announced the initial closing of a PIPE financing led by Nant Capital, LLC, raising...
Novo Nordisk adopts ‘Novo’ identity and new culture framework to sharpen competitiveness
Novo Nordisk (Nasdaq: NVO) is simplifying its public identity to "Novo" and adopting a new operating culture framework, moves the Denmark-based company said...
GSK buys second Chimagen T cell engager in deal worth up to USD 750m
GSK (LSE/NYSE: GSK) has agreed to acquire a preclinical trispecific T cell engager (TCE) for multiple myeloma from Chimagen Biosciences, a privately held...
Novo exits Ascendis TransCon obesity deal, returning once-monthly semaglutide rights
The newly renamed Novo has terminated its metabolic and cardiovascular disease collaboration with Ascendis Pharma (Nasdaq: ASND), returning worldwide rights...
J&J reviews PIPE-307 future after second Phase II failure, in MDD
Johnson & Johnson's muscarinic M1 receptor antagonist PIPE-307 (JNJ-5120) failed to separate from placebo in a Phase II depression trial, Contineum...
Aptar and MGH develop predictive NAM for nose-to-brain drug delivery
AptarGroup (NYSE: ATR) and Massachusetts General Hospital (MGH) have signed a research collaboration agreement to build an integrated translational platform...
One04 launches around Eleva’s Factor H program with kidney and AMD expansion plans
Germany-based One04 Therapeutics GmbH & Co. KG has launched as a clinical-stage biopharmaceutical company backed by D11Z.Ventures, following the separation...
Tyra prices USD 400m offering to fund late-stage push for dabogratinib across three indications
Carlsbad, California-based Tyra Biosciences (Nasdaq: TYRA) announced the pricing of a USD 400 million underwritten public offering of common stock and...
The AllSci Brief
Free, systematic R&D and deal news. Daily.